These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 10725201)
1. A point mutation in VP1 of coxsackievirus B4 alters antigenicity. Halim S; Ramsingh AI Virology; 2000 Mar; 269(1):86-94. PubMed ID: 10725201 [TBL] [Abstract][Full Text] [Related]
2. Differential recruitment of B and T cells in coxsackievirus B4-induced pancreatitis is influenced by a capsid protein. Ramsingh AI; Lee WT; Collins DN; Armstrong LE J Virol; 1997 Nov; 71(11):8690-7. PubMed ID: 9343227 [TBL] [Abstract][Full Text] [Related]
3. Identification of serotype-specific and nonserotype-specific B-cell epitopes of coxsackie B virus using synthetic peptides. Haarmann CM; Schwimmbeck PL; Mertens T; Schultheiss HP; Strauer BE Virology; 1994 May; 200(2):381-9. PubMed ID: 7513917 [TBL] [Abstract][Full Text] [Related]
4. Formation of immunogenic virus-like particles by inserting epitopes into surface-exposed regions of hamster polyomavirus major capsid protein. Gedvilaite A; Frömmel C; Sasnauskas K; Micheel B; Ozel M; Behrsing O; Staniulis J; Jandrig B; Scherneck S; Ulrich R Virology; 2000 Jul; 273(1):21-35. PubMed ID: 10891404 [TBL] [Abstract][Full Text] [Related]
5. Identification of a single amino acid residue in the capsid protein VP1 of coxsackievirus B4 that determines the virulent phenotype. Caggana M; Chan P; Ramsingh A J Virol; 1993 Aug; 67(8):4797-803. PubMed ID: 8392614 [TBL] [Abstract][Full Text] [Related]
6. Immune recognition of swine vesicular disease virus structural proteins: novel antigenic regions that are not exposed in the capsid. Jiménez-Clavero MA; Douglas A; Lavery T; Garcia-Ranea JA; Ley V Virology; 2000 Apr; 270(1):76-83. PubMed ID: 10772981 [TBL] [Abstract][Full Text] [Related]
7. Attachment of coxsackievirus B3 variants to various cell lines: mapping of phenotypic differences to capsid protein VP1. Schmidtke M; Selinka HC; Heim A; Jahn B; Tonew M; Kandolf R; Stelzner A; Zell R Virology; 2000 Sep; 275(1):77-88. PubMed ID: 11017789 [TBL] [Abstract][Full Text] [Related]
8. Coxsackievirus immunization delays onset of diabetes in non-obese diabetic mice. Davydova B; Härkönen T; Kaialainen S; Hovi T; Vaarala O; Roivainen M J Med Virol; 2003 Apr; 69(4):510-20. PubMed ID: 12601759 [TBL] [Abstract][Full Text] [Related]
9. Coxsackievirus B4 heterogeneity: effect of passage on neutralization and mortality. Hartig PC; Webb SR Acta Virol; 1986 Nov; 30(6):475-86. PubMed ID: 2881467 [TBL] [Abstract][Full Text] [Related]
10. Coxsackievirus B4 in southern Taiwan: molecular epidemiology. Chu PY; Tsai YL; Chen HL; Ke GM; Hsu CY; Chen YT; Wang CF; Su HJ; Chou LC; Hsu LC; Lin KH J Clin Virol; 2009 May; 45(1):16-22. PubMed ID: 19375382 [TBL] [Abstract][Full Text] [Related]
11. The CD4-mediated immune response is critical in determining the outcome of infection using Theiler's viruses with VP1 capsid protein point mutations. Rodriguez M; Roos RP; McGavern D; Zoecklein L; Pavelko K; Sang H; Lin X Virology; 2000 Sep; 275(1):9-19. PubMed ID: 11017783 [TBL] [Abstract][Full Text] [Related]
12. Molecular epidemiology of coxsackievirus B4 and disclosure of the correct VP1/2A(pro) cleavage site: evidence for high genomic diversity and long-term endemicity of distinct genotypes. Mulders MN; Salminen M; Kalkkinen N; Hovi T J Gen Virol; 2000 Mar; 81(Pt 3):803-12. PubMed ID: 10675418 [TBL] [Abstract][Full Text] [Related]
13. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Gromowski GD; Barrett AD Virology; 2007 Sep; 366(2):349-60. PubMed ID: 17719070 [TBL] [Abstract][Full Text] [Related]
14. What lessons can be learned from animal model studies in viral heart disease? Gauntt C; Higdon A; Bowers D; Maull E; Wood J; Crawley R Scand J Infect Dis Suppl; 1993; 88():49-65. PubMed ID: 8390719 [TBL] [Abstract][Full Text] [Related]
15. Selection of coxsackievirus B4 variants with monoclonal antibodies results in attenuation. Prabhakar BS; Srinivasappa J; Ray U J Gen Virol; 1987 Mar; 68 ( Pt 3)():865-9. PubMed ID: 3029310 [TBL] [Abstract][Full Text] [Related]
16. Enterovirus infections with beta-cell tropic strains are frequent in siblings of children diagnosed with type 1 diabetes children and in association with elevated levels of GAD65 antibodies. Frisk G; Tuvemo T J Med Virol; 2004 Jul; 73(3):450-9. PubMed ID: 15170642 [TBL] [Abstract][Full Text] [Related]
17. Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines. Dowling W; Thompson E; Badger C; Mellquist JL; Garrison AR; Smith JM; Paragas J; Hogan RJ; Schmaljohn C J Virol; 2007 Feb; 81(4):1821-37. PubMed ID: 17151111 [TBL] [Abstract][Full Text] [Related]
18. Mapping of antigenic domains in poliovirus VP1 involved in structural rearrangements during virus morphogenesis and antigenic alterations of the virion. Ketterlinus R; Wiegers K Virology; 1994 Oct; 204(1):27-37. PubMed ID: 7522372 [TBL] [Abstract][Full Text] [Related]
19. Mapping of a neutralizing antigenic site of Coxsackievirus B4 by construction of an antigen chimera. Reimann BY; Zell R; Kandolf R J Virol; 1991 Jul; 65(7):3475-80. PubMed ID: 1645779 [TBL] [Abstract][Full Text] [Related]
20. A critical role for inducible nitric oxide synthase in host survival following coxsackievirus B4 infection. Flodström M; Horwitz MS; Maday A; Balakrishna D; Rodriguez E; Sarvetnick N Virology; 2001 Mar; 281(2):205-15. PubMed ID: 11277693 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]